Chief Technical Officer
Avg Cost/Share
$5.37
Shares
973
Total Value
$5,224.43
Owned After
156,060
SEC Form 4
Chief Technical Officer
Avg Cost/Share
$3.34
Shares
2,733
Total Value
$9,136.79
Owned After
156,060
VP, Pharmaceutical Development
Avg Cost/Share
$2.92
Shares
4,737
Total Value
$13,832.04
Owned After
156,060
SEC Form 4
VP, Pharmaceutical Development
Avg Cost/Share
$2.34
Shares
6,300
Total Value
$14,742.00
Owned After
156,060
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Cappello Joseph | GNLX | Chief Technical Officer | Nov 17, 2025 | Sell | $5.37 | 973 | $5,224.43 | 156,060 | |
| Cappello Joseph | GNLX | Chief Technical Officer | Aug 21, 2025 | Sell | $3.34 | 2,733 | $9,136.79 | 156,060 | |
| Cappello Joseph | GNLX | VP, Pharmaceutical Development | May 12, 2025 | Sell | $2.92 | 4,737 | $13,832.04 | 156,060 | |
| Cappello Joseph | GNLX | VP, Pharmaceutical Development | Dec 16, 2024 | Sell | $2.34 | 6,300 | $14,742.00 | 156,060 |